
Novel gene therapy sparks hope—but raises safety questions. Srivastava et al.’s trial using CD68-driven lentiviral expression of porcine factor VIII in autologous CD34+ cells marks a major step in hemophilia A research. However, overexpression in CD68+ monocyte–macrophage cells may increase thrombosis risk, especially during inflammation, and could provoke immune responses due to antigen-presenting cell involvement. Ongoing trials should closely monitor thrombotic and immunologic complications.
Like
Save
Share